Skip to content

US · QDEL · MEDICAL - INSTRUMENTS & SUPPLIES

QuidelOrtho Corporation (QDEL) intrinsic value and stock valuation

$8.32as of 2026-11-21 · Mkt cap 837.73M

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

QuidelOrtho Corporation DCF and intrinsic value

InvestorsCraft values QDEL with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from QDEL’s statements →

QuidelOrtho Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies San Diego, CA 92121 quidelortho.com

How the business is doing

Fiscal 2010–2025, USD

Revenue
$2.73B+38.5% 5y CAGRd
20102025
Net income
-$-1.13B
20102025
Free cash flow
-$-83M
20102025
Total equity
$1.92B+28% 5y CAGRd
20102025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2010–2025, USD
20252024202320212020
Revenue$2.73B$2.78B$3B$1.7B$1.66B
Operating income-$-919.2M-$-1.96B$139.1M$906M$1.06B
Net income-$-1.13B-$-2.05B-$-10.1M$704.2M$810.3M
EPSd-$-16.69M-$-30.54M-$-151.2K$16.4M$18.6M
Operating cash flow$105.2M$83M$280.2M$805.9M$629.8M
Capital expenditure-$-188.2M-$-195.1M-$-209.3M-$-292.72M-$-64.93M
Free cash flow-$-83M-$-112.1M$70.9M$513.1M$564.8M
Total assets$5.77B$6.42B$8.56B$2.43B$1.87B
Total debt$2.83B$2.68B$2.61B$139.3M$108.5M
Net debt$2.66B$2.58B$2.5B-$-663.5M-$-381.44M
Total equity$1.92B$2.98B$5.01B$1.93B$1.33B
Cash and short-term investments$202.2M$98.3M$167.3M$828.5M$489.9M
Income statement
20252024202320212020
Revenue$2.73B$2.78B$3B$1.7B$1.66B
Cost of revenue$1.46B$1.5B$1.5B$420.3M$312.8M
Gross profit$1.27B$1.29B$1.5B$1.28B$1.35B
Research and development expenses$186.2M$218.7M$246.8M$95.7M$84.3M
Selling, general and administrative expenses$746.3M$766.8M$763.2M$239.6M$200.5M
Other expenses$1.26B$2.26B$349.8M$37M$3.69M
Operating expenses$2.19B$3.25B$1.36B$372.3M$288.5M
Cost and expenses$3.65B$4.74B$2.86B$792.6M$601.3M
Interest income$0.00$0.00$2.2M$300K$0.00
Interest expense$177.6M$188.3M$178.9M$700K$1.26M
Depreciation and amortization$442M$453.4M$457.2M$52.7M$49.1M
Ebitda-$-488.1M-$-1.49B$607M$953.3M$1.1B
Operating income-$-919.2M-$-1.96B$139.1M$906M$1.06B
Total other income/expenses, net-$-188.5M-$-170.6M-$-168.2M-$-5.7M-$-20.01M
Income before tax-$-1.11B-$-2.13B-$-29.1M$900.3M$1.04B
Income tax expense$24.1M-$-79.5M-$-19M$196.1M$230M
Net income-$-1.13B-$-2.05B-$-10.1M$704.2M$810.3M
Weighted average shares outstanding$67.8M$67.2M$66.8M$42.1M$42.1M
Weighted average diluted shares outstanding$67.8M$67.2M$66.8M$42.9M$43.6M
Balance sheet
20252024202320212020
Cash and short-term investments$202.2M$98.3M$167.3M$828.5M$489.9M
Net receivables$417M$451.3M$488.4M$393.8M$529.2M
Inventory$577.6M$533.7M$577.8M$198.8M$113.8M
Total current assets$1.45B$1.22B$1.31B$1.44B$1.14B
Property, plant and equipment, net$1.51B$1.55B$1.61B$476.8M$211M
Goodwill and intangible assets$2.56B$3.39B$5.43B$435.7M$459.5M
Long-term investments$0.00$21.7M$7.4M$37.9M$0.00
Total non-current assets$4.32B$5.2B$7.25B$990.1M$728.8M
Total assets$5.77B$6.42B$8.56B$2.43B$1.87B
Accounts payable$279.4M$246M$294.8M$101.5M$86.3M
Short-term debt$207.6M$372.9M$166.5M$10.3M$7.8M
Deferred revenue$37.8M$33.5M$36.8M$1.9M$3.73M
Total current liabilities$966.1M$998.8M$833.8M$323.5M$337M
Long-term debt$2.63B$2.31B$2.45B$129M$100.7M
Deferred revenue, non-current$0.00$17.3M$0.00$0.00-$-38.33M
Total non-current liabilities$2.88B$2.44B$2.72B$177.5M$201.5M
Capital lease obligations$183.7M$198.3M$199.5M$138.6M$108.5M
Total liabilities$3.85B$3.44B$3.56B$501M$538.5M
Common stock$100K$100K$100K$0.00$40K
Retained earnings-$-996M$135.8M$2.19B$1.65B$945M
Accumulated other comprehensive income (loss)-$-15.4M-$-36.2M-$-30M$400K-$-430K
Total equity$1.92B$2.98B$5.01B$1.93B$1.33B
Total investments$32.4M$21.7M$55.8M$63.6M$0.00
Total debt$2.83B$2.68B$2.61B$139.3M$108.5M
Net debt$2.66B$2.58B$2.5B-$-663.5M-$-381.44M
Cash flow statement
20252024202320212020
Net income-$-1.13B-$-2.05B-$-10.1M$704.2M$810.3M
Depreciation and amortization$442M$453.4M$457.2M$54.4M$49.1M
Stock-based compensation$45.9M$42.1M$51.6M$25.4M$21M
Change in working capital-$-125.8M-$-158.7M-$-194.9M-$-2.78M-$-251.07M
Accounts receivable-$-117.5M$5.4M$160M$118.9M-$-402.09M
Inventory-$-148.3M-$-134.1M-$-211.6M-$-85.04M-$-54.9M
Accounts payable$40M-$-23.4M$3M$10.5M$52.2M
Net cash provided by operating activities$105.2M$83M$280.2M$805.9M$629.8M
Investments in property, plant and equipment-$-188.2M-$-195.1M-$-209.3M-$-292.72M-$-64.93M
Acquisitions, net$6.5M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-192.7M-$-149.9M-$-187.6M-$-319.53M-$-63.32M
Common stock issued$6.1M$5M$11.6M$7.6M$9.61M
Common stock repurchased$0.00$0.00-$-7.2M-$-103.44M-$-43.69M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$155.8M$48.8M-$-265.8M-$-173.18M-$-130.28M
Net change in cash$71.3M-$-21M-$-174.4M$312.8M$437.2M
Cash at end of period$169.8M$98.5M$119.5M$802.8M$489.9M
Operating cash flow$105.2M$83M$280.2M$805.9M$629.8M
Capital expenditure-$-188.2M-$-195.1M-$-209.3M-$-292.72M-$-64.93M
Free cash flow-$-83M-$-112.1M$70.9M$513.1M$564.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About QuidelOrtho Corporation

        QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

        CEO
        Brian J. Blaser
        Employees
        6.5K
        Beta
        0.69

        Explore

        Frequently asked questions

        What is the intrinsic value of QuidelOrtho Corporation (QDEL)?

        QuidelOrtho Corporation (QDEL) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is QDEL undervalued?

        QDEL trades at a price of $8.32 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.